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BUCCOLAM® (LICENSED OROMUCOSAL MIDAZOLAM) VERSUS RECTAL
DIAZEPAM FOR ACUTE EPILEPTIC SEIZURES: ITALIAN COST-EFFECTIVENESS
ANALYSIS
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OBJECTIVES: Current care in Italy for first-line treatment of seizures consists of
rectal diazepam with some use of intravenous treatments (diazepam, midazolam
and lorazepam) in a hospital setting. In the community there can be reluctance to
administer rectal diazepam due to dignity and social acceptability issues. BUCCO-
LAM (oromucosal midazolam), the first product to receive a Paediatric-Use Market-
ing Authorisation (PUMA), is approved for the treatment of prolonged, acute, con-
vulsive seizures (PACS) in children and may be used by parents and other carers. A
decision-tree model was developed to assess the cost effectiveness of BUCCOLAM
compared to rectal diazepam for the treatment of (PACS) initially occurring in the
community setting. METHODS: The model allows for different routes though the
treatment pathway that include whether or not 1) a carer administers treatment, 2)
an ambulance is required and patients are taken to hospital; and 3) inpatient stay
is re;uired. Clinical effectiveness data were obtained from McIntyre et al (2005) and
a Delphi panel. Costs were taken from published sources. The price proposed for
BUCCOLAM reimbursement to the Italian National Health Service is used. Rectal
diazepam is not reimbursable therefore its cost is not included. Estimates of the
number of seizures per year where BUCCOLAM might be used were taken from
published sources. RESULTS: Over one year, compared to rectal diazepam, BUC-
COLAM showed a reduction in per patient costs of €1,467. The largest saving came
from an estimated reduction in inpatient costs of €919 per patient per year. Patients
treated with BUCCOLAM also had a higher health related quality of life than those
treated with rectal diazepam; treatment with BUCCOLAM is therefore dominant.
CONCLUSIONS: Treatment with BUCCOLAM is cost saving, through a reduction in
the need for ambulance call outs and hospital stays, and is more socially acceptable
than treatment with rectal diazepam.
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COST-EFFECTIVENESS OF DIFFERENT INTERFERON-BETA THERAPIES FOR
RELAPSING-REMITTING AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS:
A MARKOV MODEL BASED ON LONG-TERM CLINICAL DATA
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OBJECTIVES: To evaluate the economic outcomes of three kind of interferon-beta
comparing to placebo: IM IFNb1-a, SC IFNb1-a, or SC IFNb1-b in patients diagnosed
with Relapsing-Remitting Multiple Sclerosis (RRMS). METHODS: A literature-based
Markov model was developed to assess the cost-effectiveness of three interferon-
betas with placebo for managing a hypothetical cohort of patients diagnosed with
RRMS in Iran. Health states were based on the Kurtzke Expanded Disability Status
Scale (EDSS), a widely accepted scale for assessing Multiple sclerosis. Disease pro-
gression transition probabilities for symptom management were obtained from
natural history studies. Treatment effects of the interferon-beta therapies were
taken from related multicenter randomized controlled trials and their long term
follow up for RRMS and Secondary progressive Multiple Sclerosis (SPMS). Transi-
tion probabilities were adjusted to account for treatment discontinuation and age
and sex adjusted death rate. Transitions among health states occurred in 2-years
cycles for fifteen cycles. Only medical direct cost has been considered for
evaluation. RESULTS: The incremental cost per quality-adjusted life-year for IM
IFNb1-a therapies is $474,819, and dominated for SC IFNb1-a, or SC IFNb1-b com-
pared with placebo. The incremental cost per prevention of utility loss due to
relapses is $144912, $117455, $185907, for IM IFNb1-a, SC IFNb1-a, or SC IFNb1-b
respectively compared with placebo. CONCLUSIONS: The Markov pharmacoeco-
nomics model determined that SC IFNb1-a was the best strategy of the 3 interferon-
beta therapies used to manage MS in term of relapse, however none of these med-
icines were cost-effective considering progression of disease and utilities or
avoiding utility loss due to relapses.
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THE COST-EFFECTIVENESS OF BUCCOLAM® (LICENSED OROMUCOSAL
MIDAZOLAM) FOR THE TREATMENT OF ACUTE EPILEPTIC SEIZURES IN THE UK;
A HYBRID MODEL SOLUTION
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OBJECTIVES: In the UK, two treatment options are used for acute epileptic seizures
in the community – rectal diazepam (RD) and unlicensed oromucosal midazolam
(UOM). In practice the former is rarely used, with UOM being widely recommended
by physicians and prescribed unlicensed. In September 2011, Buccolam (licensed
oromucosal midazolam) became the first product to receive a paediatric-use mar-
keting authorisation (PUMA) and is indicated for the treatment of prolonged, acute,
convulsive seizures in children (3 months to 18 years). To support the successful
submission to the Scottish Medicines Consortium, a model was constructed as-
sessing the cost-effectiveness of Buccolam for such seizures initially occurring in
the community setting. METHODS: A hybrid model was developed, including a
time-to-event simulation for the frequency and location of occurrence of seizures
along with a decision tree model that assessed the treatment pathway when a child
has a seizure. The model was informed by data from a variety of sources including
clinical effectiveness estimates from McIntyre et al. 2005 and costs based on pub-
lished Scottish data where possible. To determine current practice, a Delphi panel,
hospital audit and survey of parents of children with epilepsy were conducted. A
6-year time horizon was used in the base case. The associated cost and health-
related quality-of-life (HRQL) impacts were calculated and scenario analyses were
conducted to assess the robustness of the model. RESULTS: Buccolam showed a
reduction in costs when compared to UOM or RD: £2,046 and £8,516, respectively. It
also improved HRQL showing an increase of 0.005 and 0.036 quality adjusted life
years, respectively. Buccolam remained dominant across a range of scenario
analyses. CONCLUSIONS: Cost savings associated with treatment with Buccolam
compared to RD are driven by a reduction in the need for ambulance call-outs and
hospital stays and, compared to UOM, through reduced drug costs and wastage.
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COST MINIMIZATION ANALYSIS OF FINGOLIMOD VERSUS NATALIZUMAB IN
THE SECOND-LINE TREATMENT OF REMITTENT-RECURRENT MULTIPLE
SCLEROSIS
Crespo C1, Izquierdo G2, García-Ruiz A3, Granell M4, Brosa M1
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OBJECTIVES: To carry out a cost-minimization analysis of Fingolimod compared to
Natalizumab in the second-line treatment of Remittent-Recurrent Multiple Sclero-
sis (RRMS) in Spain. METHODS: Based on the indirect comparisons of Del Santo
2011 and Zintzaras 2012, where no significant differences between Fingolimod and
Natalizumab were observed, a cost-minimization analysis was developed for a
2-years horizon. The relapse rate (RR) applied was the same for both treatment
arms and resource use associated to Spanish costs (€2012) was modelled. The
analysis was conducted from the National Health System (NHS) perspective and a
3 % annual discount rate was applied to future costs. A Sensitivity Analysis was
performed in order to validate the robustness of the model. RESULTS: The indirect
comparison of Fingolimod with Natalizumab recorded a Confidence Interval of the
hazard ratio between 0.82 and 1.07 (p-value: NS). The pharmacological cost for a
2-years horizon was 41,107€ for Fingolimod and 42,053€ for Natalizumab. The min-
imum cost saving derived from Fingolimod prescription was of 876€, after applying
a 7.5% discount. Considering an annual mean RR of 0.22 a 43,991€ direct medical
cost was observed for Fingolimod and a 49,161€ cost for Natalizumab. Depending
on the sensitivity analysis scenarios Fingolimod generated savings of 3.2%-11%.
CONCLUSIONS: Fingolimod is an effective second-line treatment option of RRMS
compared to Natalizumab, generating savings to the NHS.
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COST-UTILITY ANALYSIS OF A THERAPEUTIC EDUCATION PROGRAM IN
PARKINSON DISEASE VERSUS TRADITIONAL CARE
Costa N1, Derumeaux-Burel H2, Canivet C2, Ory F2, Brefel-Courbon C2, Molinier L3
1INSERM, Toulouse, France, 2University hospital of Toulouse, Toulouse, France, 3INSERM-
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OBJECTIVES: Parkinson disease (PD) is a chronic progressive disorder that causes
significant disability and reduces quality of life (QOL). In Europe the prevalence of
PD is 160/100 000 among those aged 65 and older, and annual direct cost associated
to this disease ranging from 5163€ to 9975€ per patient. No cure is available to stop
the disease, and an American study shows that a patient education program re-
duced disease progression, improved health confidence, reduced medication and
decreases physician visits. The aim of this study is to assess the cost-utility of a
therapeutic education program vs. traditional care in PD patients. METHODS: A
total of 120 patients of both sexes, under medication and meeting the criteria of the
UK Parkinson’s Disease Society were recruited from two neurology departments in
University Hospital of Toulouse between 2008 and 2010. The primary outcome
measure was the incremental cost-utility ratio of therapeutic education program
vs. traditional care. The primary medical outcome was the difference between
baseline and one year SF-36 v1 score transformed to utility trough a utility function
provided by Qualitymetrics®. This prospective economic analysis adopted the
health care payer’s perspective and take into account direct medical and non-
medical costs. RESULTS: Forty-five patients were excluded because they were not
found on social health insurance database. Costs and utility were adjusted on age,
sex and disease duration. Annual adjusted cost per patient was respectively 6633,
34€ (sd1250.15) in 34 patients and 6941, 17€ (sd1125.51) in 41 patients for tradi-
tional care group and therapeutic education program group (p0.86). Adjusted
difference of utility was -0,020 (sd0.019) and 0.019 (sd0.017) for traditional care
group and therapeutic education program group respectively (p0.14). Incremen-
tal cost-utility adjusted ratio was 7880.25/QALY. CONCLUSIONS: Therapeutic ed-
ucation program for Parkinson disease patients is cost-effective. Nevertheless,
these results should be confirmed with multicenter prospective studies assessing
medical and economic consequences of these strategies.
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COST-UTILITY ANALYSIS OF FINGOLIMOD IN BRAZILIAN PATIENTS WITH
MULTIPLE SCLEROSIS
Silva NL1, Takemoto MLS2, Cruz RB2, Suzuki C3
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OBJECTIVES: To assess the cost-utility of oral fingolimod versus interferon-
(IFN-) treatments (IFN--1a 30mcg, IFN--1a 22mcg, IFN--1a 44mcg and IFN--1b
300mcg) in relapsing-remitting multiple sclerosis (RRMS) patients from the Brazil-
ian Public Healthcare System perspective.METHODS: Cost-effectiveness was eval-
uated using a Markov model, in 20-years time horizon, comparing fingolimod to
IFN- treatments. Health states were based on EDSS and relapses, and included
separate states for RRMS and Secondary Progressive MS (SPMS). In each yearly
cycle, RRMS patients can discontinue treatment; remain stable, progress to higher
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MS EDSS state, convert from RRMS to SPMS or die. Patients have a fixed annual
probability of relapse and death. RRMS patients with EDSS score 7 were eligible
for disease modifying therapies (DMTs). Patients with SPMS or EDSS score 7 re-
ceived best supportive care. Transition probabilities were based on natural history
of RRMS. Efficacy (i.e. on relapse rates and disability progression) was obtained
from a mixed treatment comparison of published results. Health utilities were
obtained from Orme et al (2007). Resources use (physician consultations; ambula-
tory care; hospitalization, other drugs, services, DMT monitoring and administra-
tion) were validated by an experts’ panel and valued using Brazilian official lists.
Annual discount rate of 5% was applied both to costs and outcomes. Probabilistic
sensitivity analysis (PSA) was performed. RESULTS:Adopting WHO threshold, base
case analysis showed fingolimod is more effective and less costly (dominant) ver-
sus IFN--1a 44mcg (incremental costs: -26,567BRL; QALY: 0.223) and cost-effec-
tiveness versus IFN--1a 30mcg; IFN--1a 22mcg and IFN--1b 300mcg, with ICER
(BRL/QALY): 29,306; 6,725 and 52,626, respectively (3 GDP/capita or BRL 57,000.00;
1USD  2.055BRL). PSA has confirmed the consistency of base case results.
CONCLUSIONS: In the treatment of patients with RRMS, fingolimod provides su-
perior effectiveness and represents good value for money in comparison with the
most common first line therapies by the health care payer in Brazil.
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THE COST-EFFECTIVENESS OF BUCCOLAM FOR THE TREATMENT OF
PROLONGED, ACUTE, CONVULSIVE EPILEPTIC SEIZURES IN SPAIN
Lopez-Bastida J1, Gil Aguirre A2, Lee D3
1Castilla-La Mancha University, Talavera de la Reina. Toledo, Spain, 2Strategic Regulatory &
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OBJECTIVES: Despite the use of anti-epileptics, approximately 20-30 % of epileptic
patients in Spain experience recurrent convulsive seizures, which require rescue
medication and, sometimes, hospitalisation. Current standard first-line treatment
of prolonged, acute, convulsive seizures (PACS) in the community setting com-
prises rectal diazepam (RD). Buccolam (licensed oromucosal midazolam) is the
only oral paediatric formulation approved for the treatment of PACS in children (3
months to18 years). We assessed the cost effectiveness of Buccolam compared to
RD in the community setting in Spain. METHODS: A decision-tree model was de-
veloped to capture quality-of-life and cost implications of PACS. We assessed the
treatment pathway when a child has a seizure in the community including
whether or not carers administer treatment; an ambulance is required; patients are
taken to hospital and require an inpatient stay. The associated cost and health-
related quality of life (HRQL) impacts were calculated. Data were obtained from
many sources including clinical-effectiveness estimates from McIntyre et al. 2005,
a Delphi panel and a survey of parents to ascertain current practice. Costs were
taken from published sources. Sensitivity analyses were conducted on both sets of
data. RESULTS: Over one year, Buccolam showed a cost reduction of €4,994 per
patient compared to RD and HRQL improvement of 0.0075 QALYs. The price of
Buccolam would need to be more than €463/patient/year to not be cost saving.
Buccolam remained dominant across a range of scenario analyses. Reduction in
hospitalisations was the primary reason for overall cost savings (67% from reduced
ward costs, 10% from reduced ICU costs). Ambulance and emergency costs were
also significantly reduced (23% of total savings). CONCLUSIONS: Treatment with
Buccolam is cost saving compared to rectal diazepam through a reduction in hos-
pitalisations and ambulance call-outs.
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COST-EFFECTIVENESS OF ONABOTULINUMTOXIN-A FOR THE PROPHYLAXIS OF
CHRONIC MIGRAINE
Ruggeri M1, Carletto A2, Marchetti M3
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OBJECTIVES: To determine the cost-effectiveness of onabotulinumtoxinA versus
placebo in patients with chronic migraine from the Italian National Health Service
and a societal perspective.METHODS: The economic analysis is based on a Markov
Model developed to evaluate costs and effects for a cohort of patients treated with
onabotulinumtoxinA or placebo over a 2 year timeframe. The model is based on six
health states (headache present on 0-3; 4-9; 10-14; 15-19; 20-23; 24-28 days/month)
and combines data from published clinical trials (PREEMPT pooled data) with direct
and indirect costs. Costs considered included medications, treatment administra-
tion, hospitalizations, GP visits, emergency room visits and loss of productivity.
Costs and effects were both discounted at 3% per year. Univariate and multivariate
probabilistic sensitivity analysis using 10,000 Monte Carlo simulations were con-
ducted to test the robustness of results. RESULTS: In the case-base model, on-
abotulinumtoxinA was associated with an incremental number of QALYs of 0,04
per patient; the expected incremental cost per patient was € 208; the expected
incremental cost per QALY gained was therefore € 2.824. The strategy of chronic
migraine treatment with onabotulinumtoxinA is dominant as compared to placebo
if the perspective of society is adopted. Results are slightly sensitive to the utility
values used for both onabotulinumtoxinA and placebo. Multivariate sensitivity
analysis showed that there is a 69% chance that onabotulinumtoxinA is cost-effec-
tive if society is willing to pay € 30.000/QALY and 68% at a willingness to pay
threshold of € 20.000/QALY. CONCLUSIONS: This study suggests that Onabotuli-
numtoxinA improve clinical outcomes at a reasonable cost, and may actually be
cost-saving when compared to placebo if the societal perspective is adopted. Its
additional costs are offset by savings associated with a decrease in resource use
and an increase in productivity.
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COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER
TREATMENT INTRAOSSEOUS BLOCKADES
Yakovlev MV1, Kulikov AU2, Sokov EL1, Kornilova LE1
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OBJECTIVES: To assess the cost-utility analysis of intraosseous blockades vs con-
servative treated of patients with low back pain over 12 months.METHODS:A total
of 62 patients between 22 and 73 years old with a diagnosis of low back pain. Low
back pain patients were randomized of two group. Patients of the first (main) group
received a course of intraosseous blockades (Sokov EL, 1996), while patients of the
second (control group) received a course of conservatively treatment (analgetics,
NSAIDs, myorelaxants, physical therapy). Measured direct costs at 1-year follow-
up. Quality of life was measured with the Oswestry low back pain disability ques-
tionnaire, converted into utilities and transformed into quality-adjusted life years
- QALY. The analysis will be performed for the health systems. Costs were mea-
sured in EUR. RESULTS:Quality of life improved significantly at 1-year follow-up in
first group. Mean QALY in the first group was 0.358 and 0.105 in the second group.
The medical costs were much lower for intraosseous blockades treatment. The
cost-utility ratio for first group was 705,7 EUR for 1 QALY, and for standard therapy
it was 3701,5 EUR for 1 QALY. The difference in QALY’s gained during 1 year be-
tween both the groups was in fivefold in favor of the first group – 2995,8 EUR.
CONCLUSIONS: Use of intraosseous blockades compared with conservatively
treated offer significant long-term benefits in quality of life. The total costs for
intraosseous blockades were lower due to lower a reduction in the duration of
episodes the low back pain than conservatively treatments. Lower total costs and
better utility resulted in a better cost-utility for intraosseous blockades treatment.
Our analysis have demonstrated the cost-utility of intraosseous blockades.
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COST-UTILITY ANALYSIS AND COST-MINIMISATION ANALYSIS OF SABRIL®
(VIGABATRIN) IN DRUG-RESISTANT EPILEPSY FROM PAYER’S PERSPECTIVE IN
POLAND
Kawalec P1, Holko P2, Lis J3, Glasek M4
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OBJECTIVES: To determine cost-utility of Sabril®in the treatment of drug-resistant
epilepsy compared to lamotrigine, gabapentin, topiramate, tiagabine, oxcarbaz-
epine or levetiracetam in Polish conditions.METHODS: In order to determine long-
term costs and health effects of interventions, a Markov model was built and it
assumed two-step treatment of epileptics. The Cost Effectiveness Analysis Registry
Database was searched to find health state utilities. Costs in the analysis were
presented from Polish payer’s perspective, in lifetime horizon which was divided
into 3-month cycles. Only direct medical costs regarding 1st and 2nd line drug
costs, diagnostic costs, ambulatory and hospital treatment were taken into ac-
count. Costs and health effects were discounted at 5% and 3.5% rate, respectively.
A cost-utility analysis was conducted for comparison with gabapentin and lam-
otrigine while a cost-minimisation analysis was an analytical technique for com-
parisons with topiramate, tiagabine, oxcarbazepine and levetiracetam. Cost of ad-
verse events after vigabatrin administration was not taken into consideration due
to heterogenous information about risk of adverse events. RESULTS: Epilepsy ther-
apy with vigabatrin brought 0.0172QALYG comparing to gabapentin however it was
more expensive by 1526.75PLN. The administration of lamotrigine was less costly
in reference to vigabatrin (by 532.45PLN) and health effects of treatment with lam-
otrigine were superior (by 0.0091QALY). Incremental costs of vigabatrin adminis-
tration were positive in comparison to topiramate and tiagabine (3637PLN and
1831PLN) and negative in reference to oxcarbazepine and levetiracetam (-1461PLN
and -2942PLN). CONCLUSIONS: The administration of vigabatrin in drug-resistant
epilepsy was cost-effective in comparison to gabapentin however it was dominated
by treatment with lamotrigine. Epilepsy therapy with vigabatrin was more expen-
sive than treatment with topiramate or tiagabine while it was less expensive treat-
ment option than the administration of oxcarbazepine and levetiracetam.
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DIFFERENTIAL OUTCOMES IN PATIENTS WITH ALZHEIMER’S DISEASE (AD)
TREATED WITH DONEPEZIL 23
Copher R1, Li X1, Powers A1, Clionsky E2
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OBJECTIVES: To examine use of donepezil 23 (D23) in a real-world setting among
medicare and commercially insured patients. METHODS: Patients diagnosed with
Alzheimer’s disease (ICD-9-CM 331.xx),  50 years old initiating D23 (index date)
during 7/1/2010-5/31/2011 with 3 months pre- and 6 months post-index eligibility
were identified from Humana claims database (medicare 60%, commercial 40%).
Demographic characteristics were measured pre-index. Clinical characteristics
were measured pre- and post-index. Patients were categorized into 2 cohorts: con-
tinued (CON), discontinued (DIS). Discontinuation was defined as a gap of 30 days
post-index. Outcomes assessed: time on 10 mg donepezil (pre-index), AD-related
health care resource utilization and costs, length of therapy and time to discontin-
uation and use of memantine. RESULTS:A total of 479 patients were identified: 204
CON, 275 DIS. Mean age [SD] was less for CON (78.8 [7.5] v 80.5 [7.3]; p0.012) with
no differences in comorbidity scores (0.37). 59.3% of CON patients, and 67.3% of DIS
patients were female (p0.073). Over half used memantine, with greater percent-
age of CON patients using memantine compared to DIS patients pre-(68.1% v 52.0%;
p0.0004) and post-index (77.0% v 58.9%; p0.0001). More CON patients had  60
days of pre-index 10 mg donepezil use (62.2% v 45.4%; p0.0003). More DIS patients
had an ER visit (10.2% v 3.9%; p0.035) compared to CON patients. Length of stay in
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